Previous Close | 1.1400 |
Open | 1.1000 |
Bid | 0.8280 x 200 |
Ask | 1.4500 x 200 |
Day's Range | 1.1000 - 1.1999 |
52 Week Range | 0.5310 - 3.2900 |
Volume | |
Avg. Volume | 50,164 |
Market Cap | 28.354M |
Beta (5Y Monthly) | 1.04 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.9900 |
Earnings Date | May 13, 2024 - May 17, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 4.83 |
LOS ALTOS, Calif., April 16, 2024--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today highlights a presentation of a clinical data abstract at the recent 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting, held March 23-27, 2024 in Salt Lake City, Utah. Clinical data was presented by David Sperling, MD, Associate Professor of Radi
LOS ALTOS, Calif., April 15, 2024--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced the closing of its previously announced private placement of approximately $11.1 million in gross proceeds.
LOS ALTOS, Calif., April 08, 2024--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced the execution of definitive subscription agreements with accredited investors for a private placement which is expected to result in gross proceeds of approximately $11.1 million to RenovoRx, before deducting offering expenses.